Get the app
public
ios_share
OncLive® On Air
chevron_right
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
Jun 12, 2023
11:00
forum
Ask episode
play_arrow
Play
view_agenda
Chapters
auto_awesome
Transcript
info_circle
Episode notes
1
Introduction
00:00 • 3min
chevron_right
2
Epcot-Nhl1 Trial and Role in Large B-Sil Lymphoma
02:44 • 2min
chevron_right
3
Epcot-Nhl1: A Comprehensive Cancer Treatment
04:30 • 4min
chevron_right
4
Enclive on Air: A Look at the Future of Lymphoma Treatments
08:55 • 2min
chevron_right
Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.
OncLive® On Air